FDA approval summary: Crizotinib for the treatment of metastatic non-small cell lung cancer with anaplastic lymphoma kinase rearrangements

Oncologist

Volumn 19, Issue 10, 2014, Pages e5-e11

  Kazandjian, Dickran ^a   Blumenthal, Gideon M ^a   Chen, Huan Yu ^a   He, Kun ^a   Patel, Mona ^a   Justice, Robert ^a   Keegan, Patricia ^a   Pazdur, Richard ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Crizotinib; EML4 ALKfusion protein; Molecular targeted therapy; Neoplasm metastasis; Non small cell lung carcinoma

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; CRIZOTINIB; DOCETAXEL; PEMETREXED; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE; TAXOID;

ARTICLE; CANCER CHEMOTHERAPY; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DISEASE CONTROL; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG WITHDRAWAL; EDEMA; FATIGUE; FUNCTIONAL STATUS ASSESSMENT; HEALTH STATUS; HUMAN; INTERSTITIAL LUNG DISEASE; LIVER TOXICITY; NAUSEA AND VOMITING; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QT PROLONGATION; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR GROWTH; VISUAL DISORDER; ADULT; AGED; CARCINOMA, NON-SMALL-CELL LUNG; COMPARATIVE STUDY; DRUG APPROVAL; FEMALE; FOOD AND DRUG ADMINISTRATION; GENETICS; LUNG NEOPLASMS; MALE; METASTASIS; MIDDLE AGED; TREATMENT OUTCOME; UNITED STATES; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; DRUG APPROVAL; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PEMETREXED; PROTEIN KINASE INHIBITORS; PYRAZOLES; PYRIDINES; RECEPTOR PROTEIN-TYROSINE KINASES; TAXOIDS; TREATMENT OUTCOME; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION; YOUNG ADULT;

EID: 84928893512     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2014-0241     Document Type: Article

References (22)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63: 11-30.
2. Siegel R, MaJ, Zou Z et al. Cancer statistics, 2014. CA Cancer J Clin 2014; 64: 9-29.
3. American Lung Association. Lung cancer fact sheet. Available at http://www. lung. org/lungdisease/lung-cancer/resources/facts-figures/lungcancer-fact-sheet. html. Accessed March 28, 2014.
4. American Cancer Society. What are the key statistics about lung cancer? Available at http://www. cancer. org/cancer/lungcancer-non-smallcell/detailedguide/non-small-cell-lung-cancer-keystatistics. Accessed March 28, 2014.
5. Schiller JH, Gandara DR, Goss GD et al. Nonsmall-cell lung cancer: Then and now. J Clin Oncol 2013; 31: 981-983.
6. Hanna N, Shepherd FA, Fossella FV et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004; 22: 1589-1597.
7. PaoW, Miller V, ZakowskiM et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 2004; 101: 13306-13311.
8. Linardou H, Dahabreh IJ, Bafaloukos D et al. Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC. Nat Rev Clin Oncol 2009; 6: 352-366.
9. Zhou C, Wu YL, Chen G et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-smallcell lung cancer (OPTIMAL, CTONG-0802): A multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011; 12: 735-742.
10. PaoW, Girard N. New driver mutations in nonsmall-cell lung cancer. Lancet Oncol 2011; 12: 175-180.
11. Morris SW, Kirstein MN, Valentine MB et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science 1994; 263: 1281-1284.
12. Soda M, Choi YL, Enomoto M et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007; 448: 561-566.
13. Christensen JG, Zou HY, Arango ME et al. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma. Mol Cancer Ther 2007; 6: 3314-3322.
14. Malik SM, Maher VE, Bijwaard KE et al. U. S. Food and Drug Administration approval: Crizotinib for treatment of advanced or metastatic non-small cell lung cancer that is anaplastic lymphoma kinase positive. Clin Cancer Res 2014; 20: 2029-2034.
15. Shaw AT, Kim DW, Nakagawa K et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013; 368: 2385-2394.
16. ShawAT, Engelman JA. ALK in lung cancer: Past, present, and future. J Clin Oncol 2013; 31: 1105-1111.
17. Camidge DR, Kono SA, Lu X et al. Anaplastic lymphoma kinase gene rearrangements in nonsmall cell lung cancer are associatedwith prolonged progression-free survival on pemetrexed. J Thorac Oncol 2011; 6: 774-780.
18. Lee JO, Kim TM, Lee SH et al. Anaplastic lymphoma kinase translocation: A predictive biomarker of pemetrexed in patients with non-small cell lung cancer. J Thorac Oncol 2011; 6: 1474-1480.
19. Bang Y, Kwak EL, Shaw AT et al. Clinical activity of the oral ALK inhibitor PF-02341066 in ALKpositive patients with non-small cell lung cancer (NSCLC). J Clin Oncol 2010; 28(suppl 18): 3a.
20. Kwak EL, Bang YJ, Camidge DR et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010; 363: 1693-1703.
21. Roberts SA, Allen JD, Sigal EV. Despite criticism of the FDA review process, new cancer drugs reach patients sooner in the United States than in Europe. Health Aff (Millwood) 2011; 30: 1375-1381.
22. Aggarwal SR. A survey of breakthrough therapy designations. Nat Biotechnol 2014; 32: 323-330.